Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial
Hospitalized patients treated with Evusheld had a shorter median time to SARS-CoV-2 viral clearance. As Evusheld antiviral activity is mediated by the level of neutralization activity, its impact on viral clearance varies largely according to the variant of infection.
Authors
- Clément Massonnaud (ORCID: https://orcid.org/0000-0003-0292-9668)
- Guillaume Lingas (ORCID: https://orcid.org/0000-0001-8566-6220)
- Alexandre Gaymard (ORCID: https://orcid.org/0000-0002-8194-6126)
- Pascal Poignard (ORCID: https://orcid.org/0000-0002-0021-7192)
- France Mentré (ORCID: https://orcid.org/0000-0002-7045-1275)
- Maude Bouscambert‐Duchamp
- Nathan Peiffer‐Smadja (ORCID: https://orcid.org/0000-0003-1166-1958)
- Maya Hites (ORCID: https://orcid.org/0000-0001-6961-6039)
- Florence Ader (ORCID: https://orcid.org/0000-0002-4778-4338)
- M. Beaulieu (ORCID: https://orcid.org/0009-0003-1758-8146)
- Guislaine Carcelain (ORCID: https://orcid.org/0000-0002-3192-3858)
- Jérémie Guedj (ORCID: https://orcid.org/0000-0002-5534-5482)
Institutions
- Université Claude Bernard Lyon 1 (FR)
- École Normale Supérieure de Lyon (FR)
- Centre National de la Recherche Scientifique (FR)
- Université Libre de Bruxelles (BE)
- Inserm (FR)
- Université Paris Cité (FR)
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
- Centre Hospitalier Universitaire de Grenoble (FR)
- CEA Grenoble (FR)
- National Institute for Health and Care Research (GB)
- Sorbonne Université (FR)
- Hôpital de la Croix-Rousse (FR)
- Université Sorbonne Paris Nord (FR)
- Sorbonne Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hospices Civils de Lyon (FR)
- Hôpital Robert-Debré (FR)
- Hôpital Bichat-Claude-Bernard (FR)
- Institut de Biologie Structurale (FR)
- Centre International de Recherche en Infectiologie (FR)
- Imperial College London (GB)
- Université Grenoble Alpes (FR)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2024-09-05
- DOI
- https://doi.org/10.1093/jac/dkae301
- Citations
- 4
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.56
Funders
- AstraZeneca
- European Commission
- Los Alamos National Laboratory